Patent intelligence · US
US 11826429
Pharmaceutical composition comprising brinzolamide
Pharmaceutical composition comprising brinzolamide
Patent details — US 11826429
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 28, 2023
- Expiration
- Nov 23, 2043
- Applicant
- SENTISS PHARMA PRIVATE LIMITED
- Claims
- 25
- CPC classes
- A61K, A61K31/542, A61K47/26, A61K47/32
Quick answer
US 11826429 (Pharmaceutical composition comprising brinzolamide) is held by SENTISS PHARMA PRIVATE LIMITED. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SENTISS PHARMA PRIVATE LIMITED
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/542, A61K47/26, A61K47/32, A61K47/34, A61K9/0048
More from SENTISS PHARMA PRIVATE LIMITED
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 11826429?
US 11826429 (Pharmaceutical composition comprising brinzolamide) is held by SENTISS PHARMA PRIVATE LIMITED. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11826429?
SENTISS PHARMA PRIVATE LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 11826429 expire?
Our index shows an expiration date of Nov 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.